Share this article and save a life!
FQHCs are about to face a 340B cash flow nightmare.
HRSA’s new 340B rebate pilot just flipped the script on how community health centers buy medications, and the timing couldn’t be worse.
Starting January 1, select FQHCs must now pay full Wholesale Acquisition Cost upfront for nine critical drugs, including insulin NovoLog and arthritis drug Stelara. Then wait 55+ days for rebates.
Think about that math for a moment.
An FQHC serving 5,000 diabetic patients could be floating $500,000+ in drug costs every month. For health centers already operating on 2% margins, this is devastating.
The operational burden is equally crushing:
• Submit 11 data fields per claim through a new Beacon system
• Track every prescription from purchase to rebate
• Maintain compliance with unchanged HRSA audit standards
• Coordinate finance, pharmacy, and IT teams for a complete workflow overhaul
Here’s the kicker: The program is currently paused due to legal challenges, but FQHCs must stay ready for immediate restart.
So health centers are stuck preparing for a program that may or may not happen, upgrading systems for rules that may or may not stick, and budgeting for cash flow disruptions that may or may not materialize.
This uncertainty is paralyzing.
Community health centers use 340B savings to fund vaccines, mental health services, and care for the uninsured. Every dollar delayed in rebates is a dollar not serving vulnerable patients.
The irony? 340B was created to help safety net providers stretch scarce federal resources. Now it’s stretching their CFOs to the breaking point.
FQHC leaders need three things immediately:
1. Emergency credit lines to manage potential cash flow gaps
2. Real-time inventory analysis of pilot drug exposure
3. Scenario planning for both pilot resumption and permanent changes
The 340B program has saved community health centers billions. But this rebate model threatens to undo decades of financial stability in weeks.
We’re asking the safety net to operate without a net.
♻️ Repost if FQHCs deserve predictable drug pricing, not financial chaos
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
